ESTRO 2024 - Abstract Book

S1952

Clinical - Mixed sites, palliation

ESTRO 2024

In this study, 315 of the 430 consecutive cases of rectal cancer treated with RCC also received an operative intervention (ETM + ACAD or AAP + CPC) carried out 6 to 8 weeks after the end of radiotherapy. The average age was 55 years (15-88 years). Regarding the primary stage of the tumor, 0 cases had a T1 disease, 38 cases had a T2, 280 cases had a T3, and 112 cases had a T4 disease. 324 cases had a disease N+, while 106 cases had a disease N0. The patients' pathological stages were as follows: 16 cases had YpT1 disease, 92 had YpT2 disease, 116 had YpT3 disease, and 23 had YpT4 disease. 68 people have the disease ypT0N0M0, (that is, ypCR), The overall ypCR rate for the 315 LARC patients who were diagnosed was 21,58%. The following factors were predictive of pCR: a tumor's location in the middle of the rectus, a tumor's size to be less than 3 centimeters, clinical stage T, and well differentiated tumors.

Conclusion:

The post-treatment pathological status (ypTNM) provides a reliable indicator of the tumor's radiosensibility and chemical sensitivity, which are pathological characteristics that have been identified as significantly influencing the outcomes of patients after RCC neoadjuvant treatment. The percentage of complete histological responses in our study was 21%. A complete histological response with a very good prognosis was clinically predicted by the tumor's location, size, and differentiation.

Keywords: pCR -Neoadjuvant Radiotherapy - Rectal Cancer

1935

Proffered Paper

Early Quality-of-Life after metastases-directed SBRT – results of the ESTRO & EORTC OligoCare cohort

Daniela Greto 1 , Mieke Van Hemelrijck 2 , Felix Oppong 3 , Yolande Lievens 4 , Ivica Ratosa 5,6 , Barbara Alicja Jereczek Fossa 7 , Karin Stellamans 8 , Heike Peulen 9 , Luc Verbeke 10 , Hossein hemmatazad 11 , Sara Ramella 12 , Pètra Braam 13 , Giovanni Battista Ivaldi 14 , Almudena Zapatero 15 , Shaukat Adnan 16 , Pelagia Tsoutsou 17 , Olalla Santa Cruz 18 , Gemma Sancho-Pardo 19 , Piet Ost 20 , Matthias Guckenberger 21 1 Azienda Ospedaliero Universitaria Careggi, Department of Experimental and Clinical Biomedical Sciences M Serio, University of Florence, Florence, Italy. 2 King's College London, Department of Translational Oncology & Urology Research (TOUR), London, United Kingdom. 3 European Organisation for Research and Treatment of Cancer (EORTC) Headquarter, EORTC, Brussels, Belgium. 4 Department of Radiation Oncology, Ghent University Hospital, Ghent University, Ghent, Belgium. 5 Division of Radiotherapy, Institute of Oncology Ljubljana, Department of Radiation Oncology, Ljubljana, Slovenia. 6 Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia. 7 IEO European Institute of Oncology Istituto Europeo di Oncologia IRCCS, University of Milan, Milan, Italy. 8 AZ Groeninge Campus Kennedylaan, Department of Radiation Oncology, Kortrijk, Belgium. 9 Catharina Ziekenhuis, Department of Radiation Oncology, Eindhoven, Netherlands. 10 Onze Lieve Vrouw Ziekenhuis, Department of Radiation Oncology, Aalst, Belgium. 11 Inselspital Bern, Department of Radiation Oncology, Bern, Switzerland. 12 Policlinico Universitario Campus